hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-16. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Austin had walked out of the company again, publicly stating he felt underwhelming storylines were presented to him by the creative team. For the remainder of 2002, Austin kept a low profile and did not make any public appearances. It was reported, however, by the end of the year, that Austin and McMahon met and resolved their differences. He then agreed to return to the company in early 2003. In an interview with WWE Raw Magazine, he announced deep regret over the situation that led to his departure and the manner in which he had left, and deeper regret over inaccurate speculation regarding his alleged grudges held against other WWE wrestlers, claiming he had no problem with Hall rejoining the company. However, he admitted he still held strong reservations about his singles match with Hall at WrestleMania only lasting seven minutes and felt the build-up to the match did not live up to the expectations of his fans or Hall's, and was angered by speculation suggesting he disagreed with Kevin Nash re-joining the company, insisting he and Nash have always been good friends. He did, however, maintain his displeasure with the storylines and creative changes the WWE had imposed around the time of his departure. In an interview with Vince McMahon on his podcast in 2014, Austin publicly revealed for the first time that McMahon had fined him $650,000 upon his return, but he was able to lower the amount to $250,000. Austin confessed he had a major rift with Triple H's role in the company upon his return in 2002 but insisted as of 2003, they resolved their issues.
First place was won by a team that built a remote controlled balloon, which took the group four 15 to 18 hour days to build, that carried a video camera and drill built to take a sample. It was modeled after technology used in planetary exploration. They received $250 and a lithograph of a drawing of the Great Pumpkin autographed by Charles Schulz. Multiple theories were proposed as to how the pumpkin was placed on the tower, including by helicopter. The university's president Hunter R. Rawlings III, who was over 6 feet (1.8 m) tall, joked that "it was me," and that he "stood on [his] tippy toes." Despite this, the university also stated it would consider bringing charges against whoever placed the pumpkin, and campus police investigated the incident. However, some students proposed amnesty for the culprit. One archivist for the university offered to take a sealed envelope containing the name of the person who placed the pumpkin and open it in 5 or 10 years. The pumpkin stayed at the top of the tower until springtime, slowly rotting.
==== 2024 ==== Researchers demonstrated antibody-mediated depletion of myeloid-biased hematopoietic stem cells against immune system aging with mice. An experiment by researchers at Imperial College London, the MRC London Institute of Medical Sciences, and Duke–NUS Medical School found that reduction in levels of the protein interleukin 11, which increases in the body with age and in excess is responsible for increased inflammation, reversed some aspects of aging in mice. The experiment, which involved genetically engineering some mice to block the production of the protein and allowing others to reach middle age before giving them a drug to eliminate it from their bodies, increased their lifespans by 20–25% and reversed numerous effects of aging. Precious3GPT, an artificial intelligence model designed to assist in aging research and drug discovery, was launched. A study by scientists at Stanford University found that rather than being a solely gradual and linear process, aging accelerates dramatically at two points in a human lifetime. The study, which tracked thousands of different molecules in 108 people aged between 25 and 75, found that age-related changes rise substantially in two waves, with the first occurring at around age 44 and the second at around age 60.
=== Political views === Psychologists in the happiness community feel politics should promote population happiness. Politics should also consider level of human happiness among future generations, concern itself with life expectancy, and focus on the reduction of suffering. Based on political affiliation, some studies argue conservatives, on average, are happier than liberals. A potential explanation is greater acceptance of income inequalities in society leads to a less worried nature. Luke Galen, Associate Professor of Psychology at Grand Valley State University, mentioned political commitments as important because they are a sort of secular world view that, like religion, can be generally beneficial to coping with death anxiety (see also Terror management theory and religion and happiness).
Sources: en.wikipedia.org
Wolpaw and Pinkerton turned down invitations to return to Valve early in the Alyx development. Instead, Valve recruited Rob Yescombe of The Invisible Hours, who worked on Alyx in 2017 and 2018. Yescombe's narrative was darker than previous Half-Life games, with scenes of dread, torture and horror. The antagonist was a female Combine officer named Hahn; in one proposed ending, Alyx would kill Hahn in revenge for torturing her father. Yescombe also proposed an ending in which Alyx and the G-Man would travel back in time to the events of the first Half-Life to prevent Freeman from triggering the alien invasion. After the company-wide playtest in 2018, feedback was overwhelmingly positive save for the story, which employees scored the lowest of any Valve game. Morasky described it as "dark, serious and laborious", likening it to a Zack Snyder superhero film. The designer Corey Peters said the feedback vindicated their misgivings. Valve initially planned to launch Alyx alongside its Index VR headset in June 2019, but delayed it to address the story. They re-enlisted Wolpaw and Pinkerton to rewrite the plot and dialogue while preserving the gameplay, along with Jake Rodkin and Sean Vanaman, who had joined when Valve acquired Campo Santo. Laidlaw, who retired in 2016, denied reports that he had provided consultation, saying he had confidence in Pinkerton and Wolpaw and that he did not want them "second-guessing" him. The new writing team identified three problems. First, the nature of a prequel meant that players knew the characters would survive, reducing suspense.
Stained brain slice images which include the "Hypothalamus" at the BrainMaps project The Hypothalamus and Pituitary at endotexts.org NIF Search - Hypothalamus via the Neuroscience Information Framework Space-filling and cross-sectional diagrams of hypothalamic nuclei: right hypothalamus, anterior, tubular, posterior.
== Trends in the chart of nuclides == The trends in this section refer to the following chart, which shows Z increasing to the right and N increasing downward, a 90° clockwise rotation of the above landscape-orientation charts.
The cloning process can take up to 24 hours and creates larvae that are 2/3 their original length which can help conceal them from the predator. The larvae of these sand dollars clone themselves when they sense dissolved mucus from a predatory fish. The larvae exposed to this mucus from the predatory fish respond to the threat by cloning themselves. This process doubles their population and halves their size which allows them to better escape detection by the predatory fish but may make them more vulnerable to attacks from smaller predators like crustaceans. Sand dollars will also clone themselves during normal asexual reproduction. Larvae will undergo this process when food is plentiful or temperature conditions are optimal. Cloning may also occur to make use of the tissues that are normally lost during metamorphosis. The flattened test of the sand dollar allows it to burrow into the sand and remain hidden from sight from potential predators. Predators of the sand dollar are the fish species cod, flounder, sheepshead and haddock. These fish will prey on sand dollars even through their tough exterior. Sand dollars have spines on their bodies that help them to move around the ocean floor. When a sand dollar dies, it loses the spines and becomes smooth as the endoskeleton is then exposed. During the month of August, the sand dollar will have had its highest gonad index, and in November and December is the time when sand dollars will spawn. Broadcast spawning is how sand dollars reproduce.
=== Monitoring and combination use === Docetaxel is administered via a one-hour infusion every three weeks over ten or more cycles. Treatment is given under the supervision of an oncologist. Strict monitoring of blood cell counts, liver function, serum electrolytes, serum creatinine, heart function, oxygen saturation and fluid retention is required detect adverse reactions and toxicity so that treatment can be modified or terminated if necessary. Premedication with corticosteroids is recommended before each administration of docetaxel to reduce fluid retention and hypersensitive reactions. Other medications will often be given to aid pain management and other symptoms. The treatment of breast cancer with doxorubicin and cyclophosphamide is enhanced by adjuvant treatment with docetaxel. Docetaxel is also used in combination with capecitabine, a DNA synthesis inhibitor.
Sources: en.wikipedia.org
Julian Clarence Levi (1896), architect, watercolorist, philanthropist Gilbert White (1900), painter Henry Rutgers Beekman (1903), watercolorist Ely Jacques Kahn (1904), commercial architect who designed the Municipal Asphalt Plant, the Film Center Building, 120 Wall Street, 399 Park Avenue, One Penn Plaza, and 1095 Avenue of the Americas Rockwell Kent* (1907), illustrator Eric Gugler (1911), architect who designed the current Oval Office Albert Mayer (1916), planner who designed the master plan of Chandigarh Isamu Noguchi* (1926), sculptor, namesake of the Noguchi table and Noguchi Museum, designer of the Moerenuma Park, Bayfront Park, and the Lillie and Hugh Roy Cullen Sculpture Garden Charles Alston (1929), artist Ad Reinhardt (1935), abstract expressionist artist and critic Arthur Rothstein (1935), photographer for the Farm Security Administration and Look magazine Vincent Kling (1938), architect, co-founder of KlingStubbins Ed Rice (1940), author, publisher, photojournalist and painter Charles Saxon (1940), cartoonist Burton Silverman (1949), painter George S. Zimbel (1951), photographer Jeh V. Johnson (1953), architect, and educator at Vassar College Frederick C. Baldwin (1955), photographer Edward Koren (1957), cartoonist John Giorno (1958), artist, subject of Andy Warhol's first movie, Sleep Robert A. M.
The Orange Book, formally titled Compendium of Analytical Nomenclature, contains internationally accepted definitions for terms in analytical chemistry. It has traditionally been published in an orange cover. Although the book is described as the "Definitive Rules", there have been three editions published; the first in 1978 (ISBN 0-08022-008-8), the second in 1987 (ISBN 0-63201-907-7) and the third in 1998 (ISBN 0-86542-615-5). The third edition is also available online. A Catalan translation has also been published (1987, ISBN 84-7283-121-3).
=== Changing medical practices === Atenolol has been given as an example of how slow healthcare providers are to change their prescribing practices in the face of medical evidence that indicates that a drug is not as effective as others in treating some conditions. In 2012, 33.8 million prescriptions were written to American patients for this drug. In 2014, it was in the top (most common) 1% of drugs prescribed to Medicare patients. Although the number of prescriptions has been declining steadily since limited evidence articles contesting its efficacy was published, it has been estimated that it would take 20 years for doctors to stop prescribing it for hypertension. Despite its diminished efficacy when compared to newer antihypertensive drugs, atenolol and other beta blockers are still a relevant clinical choice for treating some conditions, since beta blockers are a diverse group of medicines with different properties that still requires further research. As a consequence, reasons for the continued popularity of beta blockers cannot be fully attributed to a slow healthcare system – patient compliance factors, such as treatment cost and duration, also affect adherence and popularity of therapy.
For example, enteric coatings only dissolve in the basic environment of the intestines. Drugs held in solution do not need to be dissolved before being absorbed. Lipid-soluble drugs are absorbed more rapidly than water-soluble drugs.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.